We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory

By LabMedica International staff writers
Posted on 29 Jul 2014
Print article
Image: Customers in clinical laboratories supporting hospitals, research institutions and government agencies are increasingly relying on ThermoFisher Scientific to achieve better diagnostics, improve patient care, and lower costs (Photo courtesy of Thermo Fisher Scientific).
Image: Customers in clinical laboratories supporting hospitals, research institutions and government agencies are increasingly relying on ThermoFisher Scientific to achieve better diagnostics, improve patient care, and lower costs (Photo courtesy of Thermo Fisher Scientific).
Thermo Fisher Scientific Inc. (Waltham, MA, USA) is introducing its Thermo Scientific and Life Technologies (Grand Island, NY, USA) products at the 2014 AACC Annual Meeting and Clinical Lab Expo. Thermo Fisher Scientific Inc. is highlighting its expanded portfolio of instruments, equipment, consumables, and software, for improving accuracy and efficiency in the clinical laboratory.

Marc N. Casper, president and CEO of Thermo Fisher Scientific comments “In the current healthcare environment, our customers in clinical laboratories supporting hospitals, research institutions, and government agencies are increasingly relying on better diagnostics to improve patient care and lower costs. We have the scale and depth of capabilities to help these customers drive accuracy and efficiency and ultimately improve the way healthcare is delivered.”

At AACC, Thermo Fisher will feature a range of products and services from its specialty diagnostics, analytical instrument, and genetic analysis portfolios including complete systems for aiding in the diagnosis of allergy and autoimmune diseases using ImmunoCAP and EliA blood tests such as the DRI Drugs of Abuse Assays, immunosuppressant assays, the CEDIA Cyclosporine Immunoassay, and the QMS Everolimus Immunoassay for therapeutic drug monitoring.

Next-generation sequencing platforms, including the Ion Torrent Personal Genome Machine and the Ion Chef automated sample preparation system for identifying genetic biomarkers of disease are also being shown. A new category of Thermo Scientific products, including high-performance liquid chromatography, mass spectrometry, and software designed and manufactured as US Food and Drug Association (FDA) Class 1 medical devices for use in laboratory-developed tests, and Thermo Scientific calibration and quality controls. In addition, the MAS LabLink Quality Assurance Program, a cloud-based application that offers an external perspective on daily QC and compares the data among peer laboratories will be revealed. Services including original equipment manufacturer (OEM) and custom services for development, manufacturing, and packaging of diagnostic products for third parties, as well as collaborative biomarker research and production services for industry and academia through the Thermo Fisher BRIMS center are introduced.

For a complete listing of products and services being showcased during AACC, please visit Thermo Fisher Scientific online (Please see Related Links below).

Related Links:

Thermo Fisher Scientific
Life Technologies


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Celiac Disease Test
AESKULISA tTg-A New Generation
New
Urine Analyzer
URIT-180

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.